IBD in 2012: Pathogenesis and management of IBD-thinking outside the box

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 2, 2013, Pages 67-78

  Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INFLIXIMAB; PLACEBO; SECUKINUMAB; STEROID; TOFACITINIB; USTEKINUMAB; VEDOLIZUMAB;

ANTIBODY PRODUCTION; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; GENETIC LOCI; HUMANS; INFLAMMATORY BOWEL DISEASES; PIPERIDINES; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84873464869     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.241     Document Type: Review

References (10)

1. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
2. Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63-70 (2012).
3. Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12) 61084-8.
4. Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616-624 (2012).
5. Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012).
6. Rutgeerts, P. on behalf of the GEMINI I working group. Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial [abstract]. Gut 61 (Suppl. 3), A65 (2012).
7. Colombel, J. F. on behalf of the GEMINI II working group. Vedolizumab Maintenance Therapy for Crohn's Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial [abstract]. Gut 61 (Suppl. 3), A32 (2012).
8. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
9. O'Connor, W. Jr et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603-609 (2009).
10. Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65-68 (2011).